Cai Yue, Chen Wanqing, Wang Xiaoxu, Xia Xue, Cui Xiang, Wu Shiyong, Li Jinghua
School of Public Health, Jilin University, Changchun 130021, China.
Center for Health Statistics and Information, National Health Commission, Beijing 100044, China.
Chin J Cancer Res. 2021 Oct 31;33(5):627-636. doi: 10.21147/j.issn.1000-9604.2021.05.09.
To describe the contemporary trends in total, inpatient, and outpatient expenditure on major subtypes of cancer in different classifications of hospitals in mainland China.
Home page of Inpatient Medical Records (HIMRs) and Hospital Annual Reports (HARs) were used to estimate hospital care expenditure on cancer. Inpatient payments and their share of cancer were calculated with the top-down method. Kriging spatial interpolation methods were used at the county level and summed at the province level. Outpatient expenditure was estimated with inpatient expenditure and the ratios of outpatient to inpatient payments in specialized cancer hospitals, stratified by province. Total expenditure on cancer was the sum of both payments. Log-linear regression was applied to estimate annual percentage change (APC) of expenditure.
Total expenses for cancer of Chinese residents reached up to 304.84 billion Chinese Yuan (CNY) in 2017, accounting for 5.8% of the total health expenses (THE). After adjusting for consumer price index (CPI), medical expenses for cancer have increased from 63.30 billion CNY in 2008 to 249.56 billion CNY in 2017 [APC: 15.2%, 95% confidence interval (95% CI): 13.4%-17.0%]. The APC was slightly higher than THE around 2013, while was lower after 2013. During 2008-2017, the ratio of inpatient to outpatient costs for cancer decreased from 4.3:1 to 3.8:1. The inpatient payments for cancer mainly happened in grade 3 general hospitals, East China, and among lung, colorectal, and stomach cancer; while the fastest increase was found in West China, and among thyroid, prostate, and colorectal cancer.
During 2008-2017, the rapid growth trend of medical expenses for cancer has been effectively controlled with the continuous deepening of medical reform and improvements of residents' health care. More attention should be paid to potential increases of medical costs caused by technological progress and demand release. Socialized and multi-channel insurance financing modes should be explored in the future.
描述中国内地不同类型医院中癌症主要亚型的总支出、住院支出和门诊支出的当代趋势。
利用住院病历首页(HIMRs)和医院年度报告(HARs)来估算癌症的医院护理支出。采用自上而下的方法计算住院费用及其在癌症支出中的占比。在县级层面使用克里金空间插值法,并在省级层面进行汇总。根据省级层面专业癌症医院的住院支出和门诊与住院费用的比率来估算门诊支出。癌症总支出为两者费用之和。应用对数线性回归来估算支出的年度百分比变化(APC)。
2017年中国居民癌症总费用达3048.4亿元人民币,占卫生总费用(THE)的5.8%。经消费价格指数(CPI)调整后,癌症医疗费用从2008年的633.0亿元人民币增至2017年的2495.6亿元人民币[APC:15.2%,95%置信区间(95%CI):13.4% - 17.0%]。2013年前后APC略高于卫生总费用,2013年之后则较低。2008 - 2017年期间,癌症住院与门诊费用之比从4.3∶1降至3.8∶1。癌症住院费用主要发生在三级综合医院、华东地区以及肺癌、结直肠癌和胃癌患者中;而增长最快的是西部地区以及甲状腺癌、前列腺癌和结直肠癌患者。
2008 - 2017年期间,随着医改的不断深入和居民医疗保障的改善,癌症医疗费用的快速增长趋势得到有效控制。应更加关注技术进步和需求释放导致的医疗成本潜在增加。未来应探索社会化、多渠道的保险筹资模式。